ArticleAnalytical chemistry2025
Thin Layer Chromatography Goes Ultrasmall to Assay Sphingosine Kinase Activation in Single Primary Leukemic Cells.
Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cell-to-cell heterogeneity in lipid signaling underlies variations in response and recurrence for many cancers, including leukemias. A highly parallel, miniaturized thin-layer chromatographic platform capable of assaying single cells was developed. Ultrasmall volumes (50 pL) of standard fluorescent lipids were separated with excellent repeatability, reproducibility, and limits of detection. Sphingosine-cyanine 5 (Sph-Cy5) was loaded into cells, and the single-cell contents were separated to identify Sph-Cy5 and two metabolites, Sph-1-phosphate-Cy5 (S1P-Cy5) and hexadecanoic acid Cy5 (HA-Cy5). In leukemic cells, the CD34+ blast cells demonstrated significantly greater conversion of Sph-Cy5 to its phosphorylated form compared to that of the CD34- cells. After treatment with a sphingosine kinase (SphK) inhibitor, the level of formation of S1P-Cy5 remained significantly greater for the inhibited CD34+ cells relative to that of the inhibited CD34- cells. Over 1200 single cells were rapidly assayed using 8 chips within 4 h. Sphingosine kinase activity in the CD34+ blast cells of 3 patients with acute myeloid leukemia was assayed with and without inhibitors. The patient cells displayed intertumor and intratumor heterogeneity, and subsets of cells with distinct enzymatic activities and products, highlighting the diversity of the cells within a clinical sample and between patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.